Rowe, Jacob M <br/><br/>
Will new agents impact survival in AML?  [electronic resource] 

 -  Best practice & research. Clinical haematology  12 2019 
 - 101094 p.  digital 
<br/><br/> Publication Type: Journal Article; Review 
<br/><br/><label>ISSN: </label>1532-1924 
<br/><br/><label>Standard No.: </label>10.1016/j.beha.2019.101094  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aniline Compounds--therapeutic use<br/>Disease-Free Survival<br/>Drug Approval<br/>Gemtuzumab--therapeutic use<br/>Humans<br/>Leukemia, Myeloid, Acute--drug therapy<br/>Pyrazines--therapeutic use<br/>Staurosporine--analogs & derivatives<br/>Survival Rate<br/>United States--epidemiology